Abstract 287P
Background
Nasopharyngeal carcinoma (NPC) has a high incidence among malignant tumors in China, accounting for the highest incidence of head and neck tumors. The treatment of recurrent NPC is difficult, and both the traditional in vitro cell line and PDX models have obvious shortcomings. Therefore, it is imperative to establish better disease models, to study further the mechanism of recurrent NPC, and to explore a more effective treatment method. Tumor organoids are tumor micro-organs in which stem cells are cultured in 3D in vitro. They have been verified by histopathology, molecular biology and genomics, and can retain most of the biological characteristics and tumor heterogeneity of primary tumors, which could be the best models for basic and clinical research. This study aimed to culture and identify NPC organoids using NPC biopsy and resected tissues.
Methods
Fifteen fresh nasopharygeal cancer tissue samples (diagnosed by pathology)were collected from NanFang hospital for 3D culture from June 2018 to December 2019. NPC organoids were collected, fixed with 10% formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. The expression of CD133/CD44/CD47/BMI-1/EBER were detected by immunohistochemistry and in situ hybridization.
Results
1.Successful establishment of nasopharyngeal carcinoma organoid culture system. A total of 50 NPC samples were collected, and 29 organoids were successfully cultured, with a success rate of 58%. There were 16 primary NPC organoids and 13 recurrent NPC organoids. The success rate of culture of primary and recurrent NPC organoids was 47.06% and 81.25%, respectively. The success rate of culture was mainly related to tissue quality and size, specimen pollution, etc. (P= 0.002). 2. The 3D cultures were identified as NPC organoids. The pathological characteristics of HE staining of 3D NPC cultures were consistent with those of parental tumor tissues, which had typical nuclear atypia. The markers, CD133/CD44/CD47/BMI-1 and EBER, were all positivelv expressed in both 3D cultures and parent tumor tissues.
Conclusions
We have successfully established a NPC organoid model which provides a good reference for future study of the molecular mechanism of NPC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Li Gang.
Funding
Nanfang Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - Mutational landscape of gastric cancer (GC) in adolescents and young adults (AYA) in Asia from 2015-2019
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
154P - A multicenter, prospective study of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer
Presenter: Yi-Hui Tang
Session: e-Poster Display Session
155P - Surgical outcomes and technical performance of robotic versus laparoscopic total gastrectomy for gastric cancer: A prospective comparative study FUGES-014
Presenter: Hua-Gen Wang
Session: e-Poster Display Session
156P - Safety and feasibility of laparoscopic spleen-preserving splenic hilar lymphadenectomy during total gastrectomy for advanced proximal gastric cancer: A randomized clinical trial
Presenter: Jian-Xian Lin
Session: e-Poster Display Session
157P - Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
Presenter: Amy Prawira
Session: e-Poster Display Session
158P - A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX study): Final report
Presenter: Atsuo Takashima
Session: e-Poster Display Session
159P - Open surgery can improve the 3-year postoperative survival in some patients with advanced gastric cancer compared with laparoscopic surgery: A multicenter, propensity score matching, in-depth analysis
Presenter: Ze-Ning Huang
Session: e-Poster Display Session
160P - Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Ning Li
Session: e-Poster Display Session
161P - Adjuvant tegafur/gimeracil/oteracil (S-1) versus platinum-based chemotherapies for resectable gastric cancer: Real-world experience and a propensity score matching analysis
Presenter: Chih Chieh Yen
Session: e-Poster Display Session
162P - Evaluation of neutrophil/lymphocyte ratio (NLR) in monitoring anastomotic leakage after radical total gastrectomy for gastric cancer
Presenter: Ru-Hong Tu
Session: e-Poster Display Session